LXEO vs SBUX · $147.7M cap vs P/E 76, rev $37.18B
Lexeo Therapeutics, Inc. Common Stock (LXEO) versus Starbucks Corporation (SBUX) — a side-by-side from cached financials, not a winner call.
Lexeo Therapeutics, Inc. Common Stock (LXEO) is a biotechnology company listed on US.
Starbucks Corporation (SBUX) is a restaurants company listed on NASDAQ. It is led by Brian R. Niccol.
LXEO does not have a complete income-statement cache yet.
Latest reported SBUX revenue for 2025-09-28 was $37.18B. Net income was $1.86B. SBUX currently screens at market cap $113.76B and trailing P/E 76.2.
LXEO currently screens at market cap $147.7M. SBUX currently screens at market cap $113.76B and trailing P/E 76.2.
Not investment advice. Open the LXEO and SBUX stock pages for the full models.
Not investment advice.